Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSET: Alpelisib Plus Sacituzumab Govitecan in HER2-Negative Breast Cancer
NCT05143229Phase 1Active, not recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Mar 2022
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of alpelisib and sacituzumab govitecan in breast cancer (3 arms), sponsored by University of Kansas Medical Center. Primary endpoint: Recommended Phase II Dose at 21 days. Started Mar 2022; status: active, not recruiting.
02
Drugs
alpelisibsacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05143229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143229.